Роль нарушений сигнального пути WNT в патогенезе лейкозов

Сноски

* Адресат для корреспонденции.

Финансирование

Работа выполнена при финансовой поддержке РНФ (проект 17-75-20124).

Конфликт интересов

Авторы заявляют, что у них нет конфликта интересов.

Соблюдение этических норм

Авторы заявляют, что данный обзор литературы не содержит собственных экспериментальных данных, полученных с использованием животных или с участием людей.

Библиографические ссылки на все использованные в обзоре данные других авторов оформлены в соответствии с ГОСТом Р 7 05_2008.

Список литературы

1. Reya, T., and Clevers, H. (2005) Wnt signalling in stem cells and cancer, Nature, 434, 843–850.

2. Rulifson, I.C., Karnik, S.K., Heiser, P.W., ten Berge, D., Chen, H., Gu, X., Taketo, M.M., Nusse, R., Hebrok, M., and Kim, S.K. (2007) Wnt signaling regulates pancreatic beta cell proliferation, Proc. Natl. Acad. Sci. USA, 104, 6247–6252.

3. Lu, D., Choi, M.Y., Yu, J., Castro, J.E., Kipps, T.J., and Carson, D.A. (2011) Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells, Proc. Natl. Acad. Sci. USA, 108, 13253–13257.

4. Zhao, Z.M., Reynolds, A.B., and Gaucher, E.A. (2011) The evolutionary history of the catenin gene family during metazoan evolution, BMC Evol. Biol., 11, 198.

5. Ozawa, M., Baribault, H., and Kemler, R. (1989) The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species, EMBO J., 8, 171–11717.

6. Cadigan, K.M., and Nusse, R. (1997) Wnt signaling: a common theme in animal development, Genes Dev., 11, 3286–3305.

7. Koyanagi, M., Haendeler, J., Badorff, C., Brandes, R.P., Hoffmann, J., Pandur, P., Zeiher, A.M., Kuhl, M., and Dimmeler, S. (2005) Non-canonical Wnt signaling enhances differentiation of human circulating progenitor cells to cardiomyogenic cells, J. Biol. Chem., 280, 16838–16842.

8. Tao, Q., Yokota, C., Puck, H., Kofron, M., Birsoy, B., Yan, D., Asashima, M., Wylie, C.C., Lin, X., and Heasman, J. (2005) Maternal wnt11 activates the canonical wnt signaling pathway required for axis formation in Xenopus embryos, Cell, 120, 857–871.

9. Kawano, Y., Kypta, R. (2003) Secreted antagonists of the Wnt signalling pathway, J. Cell Sci., 13, 2627–2634.

10. Stamos, J.L., and Weis, W.I. (2013) The β-catenin destruction complex, Cold Spring Harb. Perspect. Biol., 5, 7898.

11. Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G.H., Tan, Y., Zhang, Z., Lin, X., and He, X. (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism, Cell, 108, 837–847.

12. Angers, S., and Moon, R.T. (2009) Proximal events in Wnt signal transduction, Nat. Rev. Mol. Cell Biol., 10, 468–477.

13. Cadigan, K.M., and Waterman, M.L. (2012) TCF/LEFs and Wnt signaling in the nucleus, Cold Spring Harb. Perspect. Biol., 4, 7906.

14. Pate, K.T., Stringari, C., Sprowl-Tanio, S., Wang, K., TeSlaa, T., Hoverter, N.P., McQuade, M.M., Garner, C., Digman, M.A., Teitell, M.A., Edwards, R.A., Gratton. E., and Waterman, M.L. (2014) Wnt signaling directs a meta- bolic program of glycolysis and angiogenesis in colon cancer, EMBO J., 33, 1454–1473.

15. Yamada, T., Takaoka, A.S., Naishiro, Y., Hayashi, R., Maruyama, K., Maesawa, C., Ochiai, A., and Hirohashi, S. (2000) Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis, Cancer Res., 60, 4761–4766.

16. Holland, J.D., Gyоrffy, B., Vogel, R., Eckert, K., Valenti, G., Fang, L., Lohneis, P., Elezkurtaj, S., Ziebold, U., and Birchmeier, W. (2013) Combined Wnt/β-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome, Cell Rep., 5, 1214–1227.

17. Nunez, F., Bravo, S., Cruzat, F., Montecino, M., and De Ferrari, G.V. (2011) Wnt/β-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells, PLoS One., 6, 18562.

18. Choe, Y., and Pleasure, S.J. (2012) Wnt signaling regulates intermediate precursor production in the postnatal dentate gyrus by regulating CXCR4 expression, Dev. Neurosci., 34, 502–514.

19. Luis, T.C., Ichii, M., Brugman, M.H., Kincade, P., and Staal, F.J. (2012) Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development, Leukemia, 26, 414–421.

20. Takada, S., Stark, K.L., Shea, M.J., Vassileva, G., McMahon, J.A., and McMahon, A.P. (1994) Wnt-3a regulates somite and tailbud formation in the mouse embryo, Genes Dev., 8, 174–189.

21. Luis, T.C., Weerkamp, F., Naber, B.A., Baert, M.R., de Haas, E.F., Nikolic, T., Heuvelmans, S., De Krijger, R.R., van Dongen, J.J., and Staal, F.J. (2009) Wnt3a deficiency irreversibly impairs hematopoietic stem cell self-renewal and leads to defects in progenitor cell differentiation, Blood, 113, 546–554.

22. Schraufstatter, I., Serobyan, N., DiScipio, R., Feofanova, N., Orlovskaya, I., and Khaldoyanidi, S. (2009) Hyaluronan stimulates mobilization of mature hematopoietic cells but not hematopoietic progenitors, J. Stem Cells, 4, 191–202.

23. Shirvaikar, N., Marquez-Curtis, L.A., and Janowska-Wieczorek, A. (2012) Hematopoietic stem cell mobilization and homing after transplantation: the role of MMP-2, MMP-9, and MT1-MMP, Biochem. Res. Int., 2012, 685267.

24. Calvi, L.M., Adams, G.B., Weibrecht, K.W., Weber, J.M., Olson, D.P., Knight, M.C., Martin, R.P., Schipani, E., Divieti, P., Bringhurst, F.R., Milner, L.A., Kronenberg, H.M., and Scadden, D.T. (2003) Osteoblastic cells regulate the haematopoietic stem cell niche, Nature, 425, 841–846.

25. Kato, M., Patel, M.S., Levasseur, R., Lobov, I., Chang, B.H., Glass, D.A., Hartmann, C., Li, L., Hwang, T.H.,Brayton, C.F., Lang, R.A., Karsenty, G., and Chan, L. (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor, J. Cell Biol., 157, 303–314.

26. Abed, E., Chan, T.F., Delalandre, A., Martel-Pelletier, J., Pelletier, J.P., and Lajeunesse, D. (2011) R-spondins are newly recognized players in osteoarthritis that regulate Wnt signaling in osteoblasts, Arthritis Rheum., 63, 3865–3875.

27. Pennetier, D., Oyallon, J., Morin-Poulard, I., Dejean, S., Vincent, A., and Crozatier, M. (2012) Size control of the Drosophila hematopoietic niche by bone morphogenetic protein signaling reveals parallels with mammals, Proc. Natl. Acad. Sci. USA, 109, 3389–3394.

28. Yamane, T., Kunisada, T., Tsukamoto, H., Yamazaki, H., Niwa, H., Takada, S., and Hayashi, S.I. (2001) Wnt signaling regulates hemopoiesis through stromal cells, J. Immunol., 167, 765–772.

29. Luis, T.C., Naber, B.A., Roozen, P.P., Brugman, M.H., de Haas, E.F., Ghazvini, M., Fibbe, W.E., van Dongen, J.J., Fodde, R., and Staal, FJ. (2011) Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion, Cell Stem Cell, 9, 345–356.

30. Famili, F., Brugman, M.H., Taskesen, E., Naber, E.A., Fodde, R., and Staal, J.T. (2016) High levels of canonical Wnt signaling lead to loss of stemness and increased differentiation in hematopoietic stem cells, Stem Cell Rep., 6, 652–659.

31. Schilham, M.W., Wilson, A., Moerer, P., Benaissa-Trouw, B.J., Cumano, A., and Clevers, H.C. (1998) Critical involvement of Tcf-1 in expansion of thymocytes, J. Immunol., 161, 3984–3991.

32. Gounari, F., Aifantis, I., Khazaie, K., Hoeflinger, S., Harada, N., Taketo, M.M., and von Boehmer, H. (2001) Somatic activation of beta-catenin bypasses pre-TCR signaling and TCR selection in thymocyte development, Nat. Immunol., 2, 863–869.

33. Reya, T., O’Riordan, M., Okamura, R., Devaney, E., Willert, K., Nusse, R., and Grosschedl, R. (2000) Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism, Immunity, 13, 15–24.

34. Ranheim, E.A., Kwan, H.C., Reya, T., Wang, Y.K., Weissman, I.L., and Francke, U. (2005) Frizzled 9 knockout mice have abnormal B-cell development, Blood., 105, 2487–2494.

35. Tarafdar, A., Dobbin, E., Corrigan, P., Freeburn, R., and Wheadon, H. (2013) Canonical Wnt signaling promotes early hematopoietic progenitor formation and erythroid specification during embryonic stem cell differentiation, PLoS One., 8, 81030.

36. Paluru, P., Hudock, K.M., Cheng, X., Mills, J.A., Ying, L., Galvao, A.M., Lu, L., Tiyaboonchai, A., Sim, X., Sullivan, S.K., French, D.L., and Gadue, P. (2014) The negative impact of Wnt signaling on megakaryocyte and primitive erythroid progenitors derived from human embryonic stem cells, Stem Cell Res., 12, 441–451.

37. Macaulay, I.C., Thon, J.N., Tijssen, M.R., Steele, B.M., MacDonald, B.T., Meade, G., Burns, P., Rendon, A., Salunkhe, V., Murphy, R.P., Bennett, C., Watkins, N.A., He, X., Fitzgerald, D.J., Italiano, J.E., and Maguire, P.B. (2013) Canonical Wnt signaling in megakaryocytes regulates proplatelet formation, Blood, 121, 188–196.

38. Aoyama, K., Delaney, C., Varnum-Finney, B., Kohn, A.D., Moon, R.T., and Bernstein, I.D. (2007) The interaction of the Wnt and Notch pathways modulates natural killer versus T cell differentiation, Stem Cells, 25, 2488–2497.

39. Muller-Tidow, C., Steffen, B., Cauvet, T., Tickenbrock, L., Ji, P., Diederichs, S., Sargin, B., Kohler, G., Stelljes, M., Puccetti, E., Ruthardt, M., de Vos, S., Hiebert, S.W., Koeffler, H.P., Berdel, W.E., and Serve, H. (2004) Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells, Mol. Cell Biol., 24, 2890–2904.

40. Morgan, R.G., Pearn, L., Liddiard, K., Pumford, S.L., Burnett, A.K., Tonks, A., and Darley, R.L. (2013) γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin, Leukemia, 27, 336–343.

41. Simon, M., Grandage, V.L., Linch, D.C., and Khwaja, A. (2005) Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia, Oncogene, 24, 2410–2420.

42. Ysebaert, L., Chicanne, G., Demur, C., De Toni, F., Prade-Houdellier, N., Ruidavets, J.B., Mansat-De Mas, V., Rigal-Huguet, F., Laurent, G., Payrastre, B., Manenti, S., and Racaud-Sultan, C. (2006) Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis, Leukemia, 20, 1211–1216.

43. Xu, J., Suzuki, M., Niwa, Y., Hiraga, J., Nagasaka, T., Ito, M., Nakamura, S., Tomita, A., Abe, A., Kiyoi, H., Kinoshita, T., and Naoe, T. (2008) Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome, Br. J. Haematol., 140, 394–401.

44. Tickenbrock, L., Hehn, S., Sargin, B., Choudhary, C., Baumer, N., Buerger, H., Schulte, B., Muller, O., Berdel, W.E., Muller-Tidow, C., and Serve, H. (2008) Activation of Wnt signalling in acute myeloid leukemia by induction of Frizzled-4, Int. J. Oncol., 33, 1215–1221.

45. Fu, Y., Zhu, H., Wu, W., Xu, J., Chen, T., Xu, B., Qian, S., Li, J., and Liu, P. (2014) Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia, Leuk. Lymphoma, 55, 371–377.

46. Jost, E., Schmid, J., Wilop, S., Schubert, C., Suzuki, H., Herman, J.G., Osieka, R., and Galm, O. (2008) Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia, Br. J. Haematol., 142, 745–753.

47. Valencia, A., Roman-Gomez, J., Cervera, J., Such, E., Barragan, E., Bolufer, P., Moscardo, F., Sanz, G.F., and Sanz, M.A. (2009) Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia, Leukemia, 23, 1658–1666.

48. Guo, H., Zhang, T.J., Wen, X.M., Zhou, J.D., Ma, J.C., An, C., Zhang, W., Xu, Z.J., Lin, J., and Qian, J. (2017) Hypermethylation of secreted frizzled-related proteins predicts poor prognosis in non-M3 acute myeloid leukemia, Onco. Targets. Ther., 10, 3635–3644.

49. Liang, H., Chen, Q., Coles, A.H., Anderson, S.J., Pihan, G., Bradley, A., Gerstein, R., Jurecic, R., and Jones, S.N. (2003) Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue, Cancer Cell, 4, 349–360.

50. Griffiths, E.A., Gore, S.D., Hooker, C., McDevitt, M.A., Karp, J.E., Smith, B.D., Mohammad, H.P., Ye, Y., Herman, J.G., and Carraway, H.E. (2010) Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation, Leuk. Lymphoma, 51, 1711–1719.

51. Fan, R., Zhang, L.Y., Wang, H., Yang, B., Han, T., Zhao, X.L., Wang, W., Wang, X.Q., and Lin, G.W. (2012) Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome, Tohoku J. Exp. Med., 227, 119–128.

52. Man, C.H., Fung, T.K., Wan, H., Cher, C.Y., Fan, A., Ng, N., Ho, C., Wan, T.S., Tanaka, T., So, C.W., Kwong, Y.L., and Leung, A.Y. (2015) Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia, Blood, 125, 3928–3936.

53. Kuhnl, A., Valk, P.J., Sanders, M.A., Ivey, A., Hills, R.K., Mills, K.I., Gale, R.E., Kaiser, M.F., Dillon, R., Joannides, M., Gilkes, A., Haferlach, T., Schnittger, S., Duprez, E., Linch, D.C., Delwel. R., Lowenberg, B., Baldus, C.D., Solomon, E., Burnett, A.K., and Grimwade, D. (2015) Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia, Blood, 125, 2985–2994.

54. Yeung, J., Esposito, M.T., Gandillet, A., Zeisig, B.B., Griessinger, E., Bonnet, D., and So, C.W. (2010) β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells, Cancer Cell, 18, 606–618.

55. Wang, Y., Krivtsov, A.V., Sinha, A.U., North, T.E., Goessling, W., Feng, Z., Zon, L.I., and Armstrong, S.A. (2010) The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML, Science, 327, 1650–1653.

56. Ma, S., Yang, L.L., Niu, T., Cheng, C., Zhong, L., Zheng. M.W., Xiong, Y., Li, L.L., Xiang, R., Chen, L.J., Zhou, Q., Wei, Y.Q., and Yang, S.Y. (2015) SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML, Sci. Rep., 5, 15646.

57. Fiskus, W., Sharma, S., Saha, S., Shah, B., Devaraj, S.G., Sun, B., Horrigan, S., Leveque, C., Zu, Y., Iyer. S., and Bhalla, K.N. (2015) Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells, Leukemia, 29, 1267–1278.

58. Coluccia, M. L., Vacca, A., Dunach, M., Mologni, L., Redaelli, S. Bustos, V.H., Benati, D., Pinna, L.A., and Gambacorti-Passerini, C. (2007) Bcr-Abl stabilizes β-catenin in chronic myeloid leukemia through its tyrosine phosphorylation, EMBO J., 26, 1456–1466.

59. Jamieson, C.H., Ailles, L.E., Dylla, S.J., Muijtjens, M., Jones, C., Zehnder, J.L., Gotlib, J., Li, K., Manz, M.G., Keating, A., Sawyers, C.L., and Weissman, I.L. (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML, N. Engl. J. Med., 351, 657–667.

60. Zhao, C., Blum, J., Chen, A., Kwon, H.Y., Jung, S.H., Cook, J.M., Lagoo, A., and Reya, T. (2007) Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo, Cancer Cell, 12, 528–541.

61. Abrahamsson, A.E., Geron, I., Gotlib, J., Dao, K.H., Barroga, C.F., Newton, I.G., Giles, F.J., Durocher, J., Creusot, R.S., Karimi, M., Jones, C., Zehnder, J.L., Keating, A., Negrin, R.S., Weissman, I.L., and Jamieson, C.H. (2009) Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation, Proc. Natl. Acad. Sci. USA, 106, 3925–3929.

62. Pehlivan, M., Caliskan, C., Yuce, Z., and Sercan, H.O. (2017) Forced expression of Wnt antagonists sFRP1 and WIF1 sensitizes chronic myeloid leukemia cells to tyrosine kinase inhibitors, Tumour Biol., 39, doi 1010428317701654.

63. Uhm, K.O., Lee, E.S., Lee, Y.M., Park, J.S., Kim, S.J., Kim, B.S., Kim, H.S., and Park, S.H. (2009) Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia, J. Korean Med. Sci., 24, 493–497.

64. Quintas-Cardama, A., Kantarjian, H.M., and Cortes, J.E. (2009) Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia, Cancer Control., 16, 122–131.

65. Heidel, F.H., Bullinger, L., Feng, Z., Wang, Z., Neff, T.A., Stein, L., Kalaitzidis, D., Lane, S.W., and Armstrong, S.A. (2012) Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML, Cell Stem Cell, 10, 412–424.

66. Pehlivan, M., Sercan, Z., and Sercan, H.O. (2009) sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia. Leuk. Res., 33, 1062–1067.

67. Liu, N., Zang, S., Liu, Y., Wang, Y., Li, W., Liu, Q., Ji, M., Ma, D., and Ji, C. (2016) FZD7 regulates BMSCs-mediated protection of CML cells, Oncotarget, 7, 6175–6187.

68. Labialle, S., Gayet, L., Marthinet, E., Rigal, D., and Baggetto, L.G. (2002) Transcriptional regulators of the human multidrug resistance 1 gene: recent views, Biochem. Pharmacol., 64, 943–948.

69. Correa, S., Binato, R., Du Rocher, B., Castelo-Branco, M.T., Pizzatti, L., and Abdelhay, E. (2012) Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia, BMC Cancer, 12, 303.

70. Eadie, L.N., Hughes, T.P., and White, D.L. (2014) Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib, Clin. Pharmacol. Ther., 95, 294–306.

71. Eadie, L.N., Dang P., Saunders, V.A., Yeung, D.T., Osborn, M.P., Grigg, A.P., Hughes, T.P., and White, D.L. (2017) The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment, Leukemia, 31, 75–82.

72. Lu, D., Zhao, Y., Tawatao, R., Cottam, H.B., Sen, M., Leoni, L.M., Kipps, T.J., Corr, M., and Carson, D.A. (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. USA, 101, 3118–3123.

73. Wu, Q.L., Zierold, C., Ranheim, E.A. (2009) Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia, Blood, 13, 3031–3039.

74. Poppova, L., Janovska, P., Plevova, K., Radova, L., Plesingerova, H., Borsky, M., Kotaskova, J., Kantorova, B., Hlozkova, M., Figulova, J., Brychtova, Y., Machalova, M., Urik, M., Doubek, M., Kozubik, A., Pospisilova, S., Pavlova, S., and Bryja, V. (2016) Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV, Br. J. Haematol., 175, 851–859.

75. Khan, A., Hojjat-Farsangi, M., Daneshmanesh, A.H., Hansson, L., Kokhaei, P., Osterborg, A., Mellstedt, H., and Moshfegh, A. (2016) Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia, Tumour Biol., 37, 11947–11957.

76. Wang, L., Shalek, A.K., Lawrence, M., Ding, R., Gaublomme, J.T., Pochet, N., Stojanov, P., Sougnez, C., Shukla, S.A., Stevenson, K.E., Zhang. W., Wong, J., Sievers, Q.L., MacDonald, B.T., Vartanov, A.R., Goldstein, N.R., Neuberg, D., He, X., Lander, E., Hacohen, N., Regev, A., Getz, G., Brown, J.R., Park, H., and Wu, C.J. (2014) Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL, Blood, 124, 1089–1098.

77. Kaucka, M., Plevova, K., Pavlova, S., Janovska, P., Mishra, A., Verner, J., Prochazkova, J., Krejci, P., Kotaskova, J., Ovesna, P., Tichy, B., Brychtova, Y., Doubek, M., Kozubik, A., Mayer, J., Pospisilova, S., and Bryja, V. (2013) The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration, Cancer Res., 73, 1491–1501.

78. Rush, L.J., Raval, A., Funchain, P., Johnson, A.J., Smith, L., Lucas, D.M., Bembea, M., Liu, T.H., Heerema, N.A., Rassenti, L., Liyanarachchi, S., Davuluri, R., Byrd, J.C., and Plass, C. (2004) Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets, Cancer Res., 64, 2424–2433.

79. Seeliger, B., Wilop, S., Osieka, R., Galm, O., and Jost, E. (2009) CpG island methylation patterns in chronic lymphocytic leukemia, Leuk. Lymphoma, 50, 419–426.

80. Cruciat C.M., and Niehrs C. (2013) Secreted and trans-membrane Wnt inhibitors and activators, Cold Spring Harb. Perspect. Biol., 5, 15081.

81. Rahmatpanah, F.B., Carstens, S., Hooshmand, S.I., Welsh, E.C., Sjahputera, O., Taylor, K.H., Bennett, L.B., Shi, H., Davis, J.W., Arthur, G.L., Shanafelt, T.D., Kay, N.E., Wooldridge, J.E., and Caldwell, C.W. (2009) Large-scale analysis of DNA methylation in chronic lymphocytic leukemia, Epigenomics, 1, 39–61.

82. Gutierrez, A., Tschumper, R.C., Wu, X., Shanafelt, T.D., Eckel-Passow, J., Huddleston, P.M., Slager, S.L., Kay, N.E., and Jelinek, D.F. (2010) LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis, Blood, 116, 2975–2983.

83. Erdfelder, F., Hertweck, M., Filipovich, A., Uhrmacher, S., and Kreuzer, K.A. (2010) High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia, Hematol. Rep., 2, 3.

84. Wu, W., Zhu, H., Fu, Y., Shen, W., Miao, K., Hong, M., Xu, W., Fan, L., Young, K.H., Liu, P., and Li, J. (2016) High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid, Oncotarget, 7, 21631–21643.

85. Ng, O.H., Erbilgin, Y., Firtina, S., Celkan, T., Karakas, Z., Aydogan, G., Turkkan, E., Yildirmak, Y., Timur, C., Zengin, E., van Dongen, J.M., Staal, J.T., Ozbek, U., and Sayitoglu, M. (2014) Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia, Blood Cancer J., 4, 192.

86. Jia, M., Zhao, H.Z., Shen, H.P., Cheng, Y.P., Luo, Z.B., Li, S.S., Zhang, J.Y., and Tang, Y.M. (2015) Overexpression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in childhood acute lymphoblastic leukemia, Int. J. Lab. Hematol., 5, 631–640.

87. Giambra, V., Gusscott, S., Gracias, D., Song, R., and Weng, A.P. (2016) Lef1 is a critical mediator of Wnt/β-catenin signaling in T-cell acute lymphoblastic leukemia (T-ALL), Blood, 128, 5083.

88. Guo, X., Zhang, R., Liu, J., Li, M., Song, C., Dovat, S., Li, J., and Ge, Z. (2015) Characterization of LEF1 high expression and novel mutations in adult acute lymphoblastic leukemia, PLoS One, 10, 125429.

89. Yu, S., Zhou, X., Steinke, F.C., Liu, C., Chen, S.C., Zagorodna, O., Jing, X., Yokota, Y., Meyerholz, D.K., Mullighan, C.G., Knudson, C.M., Zhao, D.M., and Xue, H.H. (2012) The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy, Immunity, 37, 813–826.

90. Ferrando, A.A. (2009) The role of NOTCH1 signaling in T-ALL, Hematology Am. Soc. Hematol. Educ. Program., 353–361.

91. Gutierrez, A., Sanda, T., Ma, W., Zhang, J., Grebliunaite, R., Dahlberg, S., Neuberg, D., Protopopov, A., Winter, S.S., Larson, R.S., Borowitz, M.J., Silverman, L.B., Chin, L., Hunger, S.P., Jamieson, C., Sallan, S.E., and Look, A.T. (2010) Inactivation of LEF1 in T-cell acute lymphoblastic leukemia, Blood, 14, 2845–2851.

92. Gekas, C., D’Altri, T., Aligue, R., Gonzalez, J., Espinosa, L., and Bigas, A. (2016) β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1, Leukemia, 30, 2002–2010.

93. Giambra, V., Jenkins, C.E., Lam, S.H., Hoofd, C., Belmonte, M., Wang, X., Gusscott, S., Gracias, D., and Weng, A.P. (2015) Leukemia stem cells in T-ALL require active Hif1α and Wnt signaling, Blood, 125, 3917–3927.

94. Khan, N.I., Bradstock, K.F., and Bendall, L.J. (2007) Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia, Br. J. Haematol., 138, 338–348.

95. Roman-Gomez, J., Cordeu, L., Agirre, X., Jimenez-Velasco, A., Jose-Eneriz, E., Garate, L., Calasanz, M.J., Heiniger, A., Torres, A., and Prosper, F. (2007) Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia, Blood, 109, 3462–3469.

96. Kuhnl, A., Gokbuget, N., Kaiser, M., Schlee, C., Stroux, A., Burmeister, T., Mochmann, L.H., Hoelzer, D., Hofmann, W.K., Thiel, E., and Baldus, C.D. (2011) Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia, Blood, 118, 6362–6367.